Global /United States /Healthcare /Drug Manufacturers - General /RAFA
chevron_leftBack
Rafarma Pharmaceuticals, Inc. logo

Rafarma Pharmaceuticals, Inc.

RAFA
OTCMKTS: RAFA Delayed
0.0560USD 0%
As of 13 June 2026, Rafarma Pharmaceuticals, Inc. has a market cap of $4.88M USD, ranking #44576 globally and #5682 in the United States. It ranks #3947 in the Healthcare sector, and #1266 in the Drug Manufacturers - General industry.
Global Rank
44576
Country Rank
5682
Sector Rank
3947
Industry Rank
1266
Key Stats
Market Cap
$4.88MUSD
Revenue (TTM)
$133.33KUSD
Net Income (TTM)
-$117.22KUSD
Profit Margin
-88%
PS Ratio
36.6
PB Ratio
0.0
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
Website
rafarma.si open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
0% 1.8% -16% 30% 32% -27%

News

Loading...

Markets

Exchange Ticker Price
OTC Markets
MIC: OTCM
PRIMARY
RAFA
Rafarma Pharmaceuticals Inc
ISIN: US75062C1009
Shares Out.:
93.167M1
TV:
SA:
YF:
GF:
BA:
MS:
0.0560 USD
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Rafarma Pharmaceuticals, Inc.

Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells drugs, generic antibiotics, and specialty pharmaceuticals in Russia. It offers cephalosporin-based products, antibiotics of non-ß structure, and anti-cancer drugs in the form of injections, ampulla packaged products, child suspensions, tablets, and capsules. The company also provides drugs for accidental wounds, inflammatory eye diseases, and immunological disorders. The company has a collaboration agreement with PlantEXT Ltd. to research and manufacture the first medical cannabis suppositories for patients suffering from inflammatory bowel disease. Rafarma Pharmaceuticals, Inc. was formerly known as Johnston Acquisition Corp. and changed its name to Rafarma Pharmaceuticals, Inc. in October 2012. The company is based in Sandy, Utah with a manufacturing and distribution facility in Russia. As of October 19, 2020, Rafarma Pharmaceuticals, Inc. operates as a subsidiary of R. & D. Biocogency Laboratories Inc. Ltd.

Similar Companies

Industry: Drug Manufacturers - General (United States)
Name
Market Cap diff.
PE
LLY
$761.68B
16M%
38.1
JNJ
$547.28B
11M%
26.4
ABBV
$360.63B
7M%
97.4
MRK
$274.03B
6M%
15.1
PFE
$149.38B
3M%
19.5
$117.58B
2M%
16.8
Industry: Drug Manufacturers - General (Global)
Name
Market Cap diff.
PE
$321.52B
256.25B CHF
7M%
19.9
AZN
$288.84B
215.59B GBP
6M%
27.6
NOVN
$274.65B
218.9B CHF
6M%
20.5
NOVO-B
$181.82B
1.18T DKK
4M%
11.5
SAN
$110.1B
95.26B EUR
2M%
19.9
GSK
$108.46B
80.96B GBP
2M%
14.6
chevron_leftBack